| 書目名稱 | Handbook of HER2-targeted agents in breast cancer | | 編輯 | Ricardo H Alvarez,Javier Cortés,Dimitrios Zardavas | | 視頻video | http://file.papertrans.cn/422/421414/421414.mp4 | | 概述 | Includes the most up-to-date treatment and diagnostic guidelines, include American Society of Clinical Onocology (ASCO) and National Comprehensive Cancer Network (NCCN).In-depth discussion of the rece | | 圖書封面 |  | | 描述 | ?Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.? Of these cases, approximately? 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.? However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies.Handbook of HER2-Targeted Agents in Breast Cancer ?provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings. | | 出版日期 | Book 2013 | | 關(guān)鍵詞 | Biomarkers; Breast Cancer; Cancer; HER2; Oncology; pharmacotherapy | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-907673-94-8 | | isbn_softcover | 978-1-907673-93-1 | | isbn_ebook | 978-1-907673-94-8 | | copyright | Springer Healthcare 2013 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-13 16:25
發(fā)表于 2025-3-21 16:54:34
